Gilead Sciences, Inc. (NASDAQ: GILD) Program presents over 20 study abstracts – Gilead and its cell therapy unit Kites are presented at two major medical conferences: the 2025 ASCO Annual Meeting (May 30-June 3) and the 2025 EHA EHA Congress (June 12-15). The speech will cover a range of cancers, including breast cancer, solid tumors and a variety of blood cancers.

A key highlight of ASCO will be the late-stage 3-phase results of the Ascent-04 trial, which suggests that the combination of Trodelvy® and KeyTruda® significantly improves progression-free survival compared to patients with PD-L1-positive, unusable or metastatic Tropatic Tropartic trotiple breast cancer.

Additionally, researchers at the Perelman School of Medicine at the University of Pennsylvania (mediated with a kite) will share the Phase 1 findings targeting a new automotive T-cell therapy that targets two markers for patients with recurrent glioblastoma, the most aggressive brain cancer. These results will be presented in the oral course at ASCO.

Dietmar Berger, Chief Medical Officer of Gilead Sciences, MD, PhD, commented on this:

“Our portfolio of oncology works is broad and varied by design as we continue to innovate through next-generation therapies and combinations to deliver improved results and ultimately try to change the way cancer is treated. The data from ASCO and EHA will help promote cancer entrepreneurship and transform cancer antibody approaches to novel approaches with antibiotics.

Despite Gilead Sciences, Inc. (NASDAQ:GILD) The cancer drug pipeline seems promising, but the company hasn't disappointed investors financially. The company is a strong dividend payer and currently offers a quarterly dividend of $0.79 per share. It has also increased spending every year since 2015. As of May 18, the stock's dividend yield was 3.08%. Additionally, dividend yields this year have been higher than the wide market this year since the beginning of 2025, soaring nearly 51%.

Although we acknowledge that Gilder has the potential to grow, our belief lies in the belief that certain AI stocks have greater returns and limited downside risks. If you are looking for more promising AI stocks than Gilder and have 100x upside potential, check out our report Cheapest AI in stock.

Read next article: 12 Best Medium Dividend Nobles Invest Now, and 25 High Dividend Stocks Are Short Sellers Target

Disclosure. Nothing.